LT4758B - Pramoniniai gaminiai - Google Patents

Pramoniniai gaminiai Download PDF

Info

Publication number
LT4758B
LT4758B LT2000035A LT2000035A LT4758B LT 4758 B LT4758 B LT 4758B LT 2000035 A LT2000035 A LT 2000035A LT 2000035 A LT2000035 A LT 2000035A LT 4758 B LT4758 B LT 4758B
Authority
LT
Lithuania
Prior art keywords
pde5
treatment
pde5 inhibitor
sexual dysfunction
inhibition
Prior art date
Application number
LT2000035A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2000035A (en
Inventor
Jeffrey Thomas Emmick
William Ernest Pullman
Kenneth Michael Ferguson
John Steven Whitaker
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4758(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of LT2000035A publication Critical patent/LT2000035A/xx
Publication of LT4758B publication Critical patent/LT4758B/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
LT2000035A 1999-04-30 2000-04-26 Pramoniniai gaminiai LT4758B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30

Publications (2)

Publication Number Publication Date
LT2000035A LT2000035A (en) 2000-11-27
LT4758B true LT4758B (lt) 2001-02-26

Family

ID=22452153

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000035A LT4758B (lt) 1999-04-30 2000-04-26 Pramoniniai gaminiai

Country Status (47)

Country Link
EP (2) EP1173181B3 (es)
JP (2) JP4975214B2 (es)
KR (2) KR100577057B1 (es)
CN (2) CN1292264A (es)
AT (1) ATE251908T1 (es)
AU (3) AU3012900A (es)
BE (1) BE1012957A5 (es)
BR (2) BR0003046A (es)
CA (2) CA2307101C (es)
CH (2) CH692478A5 (es)
CO (1) CO5170493A1 (es)
CZ (1) CZ296534B6 (es)
DE (3) DE60005940T3 (es)
DK (2) DK1173181T6 (es)
DZ (1) DZ3171A1 (es)
EA (2) EA200000355A3 (es)
ES (2) ES2187234A1 (es)
FI (1) FI20000976A (es)
FR (1) FR2795646B1 (es)
GB (1) GB2351663A (es)
GR (1) GR1003575B (es)
HK (1) HK1041204B (es)
HR (2) HRP20000243A2 (es)
HU (2) HUP0001632A3 (es)
ID (1) ID25704A (es)
IE (1) IE20000315A1 (es)
IL (3) IL135817A0 (es)
IT (1) ITMI20000922A1 (es)
LT (1) LT4758B (es)
LU (1) LU90569B1 (es)
LV (1) LV12560B (es)
MX (2) MXPA00003997A (es)
NL (1) NL1015027C2 (es)
NO (2) NO20002097L (es)
NZ (2) NZ514882A (es)
PE (1) PE20010071A1 (es)
PL (2) PL197813B1 (es)
PT (2) PT102457A (es)
SE (1) SE0001518L (es)
SG (1) SG98384A1 (es)
SI (2) SI1173181T1 (es)
SK (1) SK285415B6 (es)
SV (1) SV2002000055A (es)
TR (1) TR200001132A2 (es)
UA (1) UA72248C2 (es)
WO (1) WO2000066099A2 (es)
ZA (2) ZA200002058B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
JP2004533402A (ja) * 2000-06-08 2004-11-04 リリー アイコス リミテッド ライアビリティ カンパニー Pdevインヒビターとしての四環系ジケトピペラジン化合物
EP1305313A1 (en) * 2000-08-02 2003-05-02 Lilly Icos LLC Fused heterocyclic derivatives as phosphodiesterase inhibitors
ES2286291T3 (es) 2001-06-05 2007-12-01 Lilly Icos Llc Compustos tetraciclicos como inhibidores de pde5.
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN102846585A (zh) 2006-03-28 2013-01-02 杰佛林制药公司 低剂量的双氯芬酸和β-环糊精的制剂
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
EP2672959A1 (en) 2011-02-10 2013-12-18 Synthon BV Granulated composition comprising tadalafil and a disintegrant
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR101663238B1 (ko) 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
JP7312198B2 (ja) * 2018-02-07 2023-07-20 スマヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 医薬製剤、医薬製剤の製造方法、およびそれを含む医薬品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043287A1 (en) 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
US5859006A (en) 1994-01-21 1999-01-12 Icos Corporation Tetracyclic derivatives; process of preparation and use
US5981527A (en) 1995-07-14 1999-11-09 Icos Corporation Cyclic GMP-specific phosphodiesterase inhibitors
US6001847A (en) 1995-07-14 1999-12-14 Icos Corporation Chemical compounds
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
ID22834A (id) * 1997-04-25 1999-12-09 Pfizer Pirazolopimidinona untuk kelainan seksual
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
CA2346350C (en) * 1998-10-05 2008-01-08 Eisai Co., Ltd. Intraoral quickly disintegrating tablets
CA2362918A1 (en) * 1999-03-08 2000-09-14 Elizabeth Stoner Methods and compositions for treating erectile dysfunction
WO2000066114A1 (en) * 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859006A (en) 1994-01-21 1999-01-12 Icos Corporation Tetracyclic derivatives; process of preparation and use
US5981527A (en) 1995-07-14 1999-11-09 Icos Corporation Cyclic GMP-specific phosphodiesterase inhibitors
US6001847A (en) 1995-07-14 1999-12-14 Icos Corporation Chemical compounds
WO1997043287A1 (en) 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOOLELL M ET AL.: "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction", INT J IMPOT RES., 1996, pages 47 - 52, XP000938747
CHENG Y, PRUSOFF WH.: "Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.", BIOCHEM PHARMACOL., 1973, pages 3099 - 3108, XP001106687, DOI: doi:10.1016/0006-2952(73)90196-2
CONTI, R.C ET AL.: "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease", AMERICAN JOURNAL OF CARDIOLOGY, 1999, pages 29 - 34
MURRAY K.J.: "Phosphodiesterase VA inhibitors.", DRUG NEWS & PERSPECTIVES, 1993, pages 150 - 156, XP002924954
WEBB, D.J ET AL.: "Sildenafil Citrate and blood pressure lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist", AMERICAN JOURNAL OF CARDIOLOGY, 1999, pages 21 - 28

Also Published As

Publication number Publication date
EP1415652A2 (en) 2004-05-06
PT102457A (pt) 2000-11-30
BR0003046A (pt) 2002-07-23
ATE251908T1 (de) 2003-11-15
MXPA01010837A (es) 2002-11-07
NO20015275D0 (no) 2001-10-29
LU90569B1 (fr) 2002-02-27
LV12560B (en) 2001-04-20
NZ514882A (en) 2003-08-29
DE60005940T3 (de) 2015-08-27
SE0001518D0 (sv) 2000-04-26
HK1041204B (zh) 2004-03-05
NO20002097L (no) 2001-10-26
WO2000066099A2 (en) 2000-11-09
HU0001632D0 (en) 2000-06-28
DK1173181T6 (en) 2015-04-27
EP1173181A2 (en) 2002-01-23
AU3012900A (en) 2000-11-02
DE10021266A1 (de) 2000-11-16
AU4490800A (en) 2000-11-17
ITMI20000922A0 (it) 2000-04-26
FR2795646B1 (fr) 2002-08-16
DK200000677A (da) 2000-10-31
HUP0001632A2 (hu) 2001-05-28
ES2208317T7 (es) 2015-09-15
IL146098A0 (en) 2002-07-25
BR0010181A (pt) 2003-02-25
CN1196487C (zh) 2005-04-13
SE0001518L (sv) 2000-10-31
AU769946C (en) 2005-01-13
CH1173181H1 (es) 2019-07-15
CA2307101C (en) 2003-01-28
IL146098A (en) 2007-06-03
CO5170493A1 (es) 2002-06-27
PL197813B1 (pl) 2008-04-30
HU230369B1 (hu) 2016-03-29
KR20010020779A (ko) 2001-03-15
DE20007861U1 (de) 2000-08-24
FI20000976A (fi) 2000-10-30
EA005416B1 (ru) 2005-02-24
CH692478A5 (de) 2002-07-15
NO20002097D0 (no) 2000-04-25
EA200000355A2 (ru) 2000-10-30
HRP20010778B1 (en) 2005-04-30
SK285415B6 (sk) 2007-01-04
NL1015027C2 (nl) 2001-02-14
CA2371684C (en) 2007-10-23
CN1384746A (zh) 2002-12-11
KR20020008396A (ko) 2002-01-30
PL352629A1 (en) 2003-08-25
CA2307101A1 (en) 2000-10-30
SV2002000055A (es) 2002-07-03
EP1173181B3 (en) 2015-03-25
ES2208317T3 (es) 2004-06-16
CN1292264A (zh) 2001-04-25
KR100577057B1 (ko) 2006-05-10
WO2000066099A3 (en) 2001-01-18
PT1173181E (pt) 2004-02-27
ZA200002058B (en) 2000-11-02
EP1173181B1 (en) 2003-10-15
HUP0001632A3 (en) 2001-12-28
ID25704A (id) 2000-11-02
NO322013B1 (no) 2006-08-07
NO322013B3 (no) 2017-11-06
SK15632001A3 (sk) 2002-02-05
ES2187234A1 (es) 2003-05-16
HU0200912D0 (en) 2002-04-29
BE1012957A5 (fr) 2001-06-05
ZA200108900B (en) 2003-03-26
GR1003575B (el) 2001-05-14
EP1415652A3 (en) 2004-05-12
FR2795646A1 (fr) 2001-01-05
IL135817A0 (en) 2001-05-20
SI20361A (sl) 2001-04-30
GB2351663A (en) 2001-01-10
TR200001132A3 (tr) 2001-01-22
JP2002543116A (ja) 2002-12-17
DE60005940T2 (de) 2004-07-29
PE20010071A1 (es) 2001-03-22
GB0010199D0 (en) 2000-06-14
DE60005940D1 (de) 2003-11-20
JP4975214B2 (ja) 2012-07-11
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
EA200101008A1 (ru) 2002-04-25
AU2004201988A1 (en) 2004-06-10
SG98384A1 (en) 2003-09-19
GR20000100153A (el) 2000-12-29
EA200000355A3 (ru) 2001-02-26
HUP0200912A3 (en) 2003-07-28
CZ20013879A3 (cs) 2002-04-17
NO20015275L (no) 2001-12-06
SI1173181T1 (en) 2004-04-30
DK1173181T3 (da) 2004-02-16
AU769946B2 (en) 2004-02-12
PL339897A1 (en) 2000-11-06
UA72248C2 (en) 2005-02-15
LT2000035A (en) 2000-11-27
CA2371684A1 (en) 2000-11-09
MXPA00003997A (es) 2002-03-08
HRP20000243A2 (en) 2001-12-31
LV12560A (en) 2000-11-20
NZ504163A (en) 2001-11-30
CZ296534B6 (cs) 2006-04-12
NL1015027A1 (nl) 2000-10-31
DZ3171A1 (es) 2000-11-09
TR200001132A2 (tr) 2001-01-22
ITMI20000922A1 (it) 2001-10-26
FI20000976A0 (fi) 2000-04-26
HUP0200912A2 (en) 2002-08-28
IE20000315A1 (en) 2001-03-07
JP2000336043A (ja) 2000-12-05

Similar Documents

Publication Publication Date Title
LT4758B (lt) Pramoniniai gaminiai
US6943166B1 (en) Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6451807B1 (en) Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US20010053780A1 (en) Daily treatment for erectile dysfunction using a PDE5 inhibitor
CZ20001536A3 (cs) Orální léčivo

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20040426